Black Diamond Therapeutics (NASDAQ:BDTX – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research report issued on Tuesday, Benzinga reports. They presently have a $11.00 price objective on the stock. HC Wainwright’s price objective points to a potential upside of 144.44% from the company’s current price.
Other analysts also recently issued research reports about the company. Piper Sandler lifted their target price on Black Diamond Therapeutics from $12.00 to $15.00 and gave the company an “overweight” rating in a research note on Monday. Raymond James initiated coverage on shares of Black Diamond Therapeutics in a research note on Wednesday, July 31st. They set an “outperform” rating and a $20.00 target price on the stock. Finally, Wedbush reiterated an “outperform” rating and set a $16.00 price target on shares of Black Diamond Therapeutics in a research report on Tuesday, September 10th.
Check Out Our Latest Stock Analysis on BDTX
Black Diamond Therapeutics Stock Down 5.5 %
Black Diamond Therapeutics (NASDAQ:BDTX – Get Free Report) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.03. As a group, equities research analysts expect that Black Diamond Therapeutics will post -1.4 earnings per share for the current year.
Institutional Trading of Black Diamond Therapeutics
Hedge funds and other institutional investors have recently made changes to their positions in the business. Susquehanna Fundamental Investments LLC acquired a new position in Black Diamond Therapeutics in the first quarter worth approximately $82,000. SG Americas Securities LLC acquired a new stake in Black Diamond Therapeutics during the 2nd quarter worth about $108,000. Jump Financial LLC raised its holdings in Black Diamond Therapeutics by 245.0% during the 4th quarter. Jump Financial LLC now owns 38,888 shares of the company’s stock worth $109,000 after buying an additional 27,616 shares during the period. Algert Global LLC purchased a new stake in Black Diamond Therapeutics during the second quarter valued at about $133,000. Finally, Pale Fire Capital SE acquired a new position in shares of Black Diamond Therapeutics in the fourth quarter worth about $144,000. 95.47% of the stock is currently owned by institutional investors.
Black Diamond Therapeutics Company Profile
Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.
Read More
- Five stocks we like better than Black Diamond Therapeutics
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Intel’s Spin-Off Strategy: A Bargain Hiding in Plain Sight?
- Best Stocks Under $5.00
- Workday’s Next-Gen AI Integration: Perfect Time to Buy the Dip?
- How to Invest in Insurance Companies: A Guide
- Seize the Growth: Twilio’s AI Innovations Are Driving Huge Upside
Receive News & Ratings for Black Diamond Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Diamond Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.